Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Less than 1 min.Read

By Investing Today

May 17, 2025

Facebook

Twitter

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Attachment

2025 05 16 SBB EN

Hot this week

News Room

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 18, 2025 0

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten...

News Room

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

May 18, 2025 0

Slowing of progression of disease observed via MRI at...

News Room

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

May 18, 2025 0

Deep, durable and consistent reductions in TTR were sustained...

News Room

Dillard’s, Inc. Announces $0.25 Cash Dividend

May 17, 2025 0

LITTLE ROCK, Ark., May 17, 2025 (GLOBE...

News Room

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

May 17, 2025 0

Data confirmed TX45’s tolerability profile and improvements in left...

Topics

News Room

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten...

News Room

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

Slowing of progression of disease observed via MRI at...

News Room

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

Deep, durable and consistent reductions in TTR were sustained...

News Room

Dillard’s, Inc. Announces $0.25 Cash Dividend

LITTLE ROCK, Ark., May 17, 2025 (GLOBE...

News Room

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

Data confirmed TX45’s tolerability profile and improvements in left...

News Room

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT...

Data suggests that single dose of RJVA-001 leads to...

News Room

Arcadis’ shareholders re-appoint Supervisory Board members and approve dividend

rcadis 2025 Annual General MeetingArcadis' shareholders re-appoint Supervisory Board...

News Room

Holding(s) in Company

TR-1: Standard form for notification of major holdings NOTIFICATION...

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

News Room May 18, 2025

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

News Room May 18, 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

News Room May 18, 2025

Dillard’s, Inc. Announces $0.25 Cash Dividend

News Room May 17, 2025

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

News Room May 17, 2025

Popular Categories

News RoomFeatured CompaniesVideos

First Merchants Corporation Announces Cash Dividend

Timbercreek Financial announces Voting Results from Annual Meeting of Shareholders

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

Dillard’s, Inc. Announces $0.25 Cash Dividend

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

Topics

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

Dillard’s, Inc. Announces $0.25 Cash Dividend

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT...

Arcadis’ shareholders re-appoint Supervisory Board members and approve dividend

Holding(s) in Company

Related Articles

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

Dillard’s, Inc. Announces $0.25 Cash Dividend

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking...

Company

Headlines

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation...

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy...

Dillard’s, Inc. Announces $0.25 Cash Dividend

Newsletter